RA Capital Nexus Fund III, L.P. (CIK 1883840) reported 72 SEC Form 4 insider transactions across 7 companies over the past 18 months (most recent 2026-06-16). Recent activity: Buy ARTV (391,019 shares), Buy ARTV (15,414 shares), Buy ARTV (124,893 shares), Buy ARTV (479,039 shares), Buy ARTV (103 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 391,019 | $3.4M |
| 2026-06-16 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 15,414 | $138,572 |
| 2026-06-16 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 124,893 | $1.1M |
| 2026-06-11 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 479,039 | $3.3M |
| 2026-06-11 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 103 | $721 |
| 2026-06-11 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 548,580 | $4.3M |
| 2026-05-13 | Artiva Biotherapeutics, Inc. (ARTV) | Director | Buy | 6.5M | $75.0M |
| 2026-03-31 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 310,700 | $7.4M |
| 2026-03-31 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 58,300 | $1.4M |
| 2026-03-02 | Bicara Therapeutics Inc. (BCAX) | Director | Buy | 300,000 | $4.8M |
| 2026-02-20 | Mineralys Therapeutics, Inc. (MLYS) | Director | Buy | 6,200 | $0 |
| 2026-02-17 | Evommune, Inc. (EVMN) | Director | Buy | 35,868 | $1,000,000 |
| 2026-02-11 | SpyGlass Pharma, Inc. (SGP) | Director | Buy | 2.5M | $0 |
| 2026-02-11 | SpyGlass Pharma, Inc. (SGP) | Director | Buy | 1.8M | $0 |
| 2026-02-11 | SpyGlass Pharma, Inc. (SGP) | Director | Buy | 3.4M | $55.1M |
| 2026-02-11 | SpyGlass Pharma, Inc. (SGP) | Director | Buy | 248,034 | $4.0M |
| 2026-01-07 | Climb Bio, Inc. (CLYM) | Director | Buy | 7,111 | $24,888 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Sell | 20.4M | $0 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Buy | 213,099 | $464,556 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Buy | 101,462 | $290,181 |
| 2025-11-24 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 150 | $5,984 |
| 2025-11-24 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 1,235 | $49,264 |
| 2025-11-24 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 801 | $31,952 |
| 2025-11-24 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 947 | $37,776 |
| 2025-11-24 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 96 | $3,888 |
Source: SEC Form 4 filings · as of 2026-06-16